Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

miR-132 suppresses transcription of ribosomal proteins to promote protective Th1 immunity.

Hewitson JP, Shah KM, Brown N, Grevitt P, Hain S, Newling K, Sharp TV, Kaye PM, Lagos D.

EMBO Rep. 2019 Apr;20(4). pii: e46620. doi: 10.15252/embr.201846620. Epub 2019 Mar 4.

PMID:
30833344
2.

Dual Imaging With 68Ga-DOTATOC and 18F-FDG PET for Planning and Follow-up of PRRT in Combination With Temozolomide Treatment in a Patient With a Metastatic Neuroendocrine Tumor.

Wei X, Hain S, Hartmann L, Hirzebruch S, Ahmadzadehfar H.

Clin Nucl Med. 2019 Jun;44(6):480-482. doi: 10.1097/RLU.0000000000002519.

PMID:
30829861
3.

Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis.

Hoffmann A, Dietrich S, Hain S, Rieger M, Hegenbart U, Sellner L, Ho AD, Müller-Tidow C, Dreger P.

Haematologica. 2019 Jul;104(7):e304-e306. doi: 10.3324/haematol.2018.209486. Epub 2019 Jan 10. No abstract available.

4.

A randomized control trial to determine the effectiveness and physiological effects of spinal manipulation and spinal mobilization compared to each other and a sham condition in patients with chronic low back pain: Study protocol for The RELIEF Study.

Clark BC, Russ DW, Nakazawa M, France CR, Walkowski S, Law TD, Applegate M, Mahato N, Lietkam S, Odenthal J, Corcos D, Hain S, Sindelar B, Ploutz-Snyder RJ, Thomas JS.

Contemp Clin Trials. 2018 Jul;70:41-52. doi: 10.1016/j.cct.2018.05.012. Epub 2018 May 21.

5.

Deriving Dorsal Spinal Sensory Interneurons from Human Pluripotent Stem Cells.

Gupta S, Sivalingam D, Hain S, Makkar C, Sosa E, Clark A, Butler SJ.

Stem Cell Reports. 2018 Feb 13;10(2):390-405. doi: 10.1016/j.stemcr.2017.12.012. Epub 2018 Jan 11.

6.

PARTICLE triplexes cluster in the tumor suppressor WWOX and may extend throughout the human genome.

O'Leary VB, Smida J, Buske FA, Carrascosa LG, Azimzadeh O, Maugg D, Hain S, Tapio S, Heidenreich W, Kerr J, Trau M, Ovsepian SV, Atkinson MJ.

Sci Rep. 2017 Aug 2;7(1):7163. doi: 10.1038/s41598-017-07295-5.

7.

Lack of effects of a "sobering" product, "Eezup!", on the blood ethanol and congener alcohol concentration.

Wunder C, Hain S, Koelzer SC, Paulke A, Verhoff MA, Toennes SW.

Forensic Sci Int. 2017 Sep;278:101-105. doi: 10.1016/j.forsciint.2017.06.024. Epub 2017 Jun 28.

PMID:
28710938
8.

Long non-coding RNA PARTICLE bridges histone and DNA methylation.

O'Leary VB, Hain S, Maugg D, Smida J, Azimzadeh O, Tapio S, Ovsepian SV, Atkinson MJ.

Sci Rep. 2017 May 11;7(1):1790. doi: 10.1038/s41598-017-01875-1.

9.

Risk and protective factors for antepartum and postpartum depression: a prospective study.

Hain S, Oddo-Sommerfeld S, Bahlmann F, Louwen F, Schermelleh-Engel K.

J Psychosom Obstet Gynaecol. 2016 Dec;37(4):119-129. doi: 10.1080/0167482X.2016.1197904. Epub 2016 Jul 4.

PMID:
27376660
10.

Longitudinal effects of dysfunctional perfectionism and avoidant personality style on postpartum mental disorders: Pathways through antepartum depression and anxiety.

Oddo-Sommerfeld S, Hain S, Louwen F, Schermelleh-Engel K.

J Affect Disord. 2016 Feb;191:280-8. doi: 10.1016/j.jad.2015.11.040. Epub 2015 Nov 28.

PMID:
26688497
11.

Effects of Osteopathic Manipulative Treatment on Diabetic Gastroparesis.

Van Ravenswaay VJ, Hain SJ, Grasso S, Shubrook JH.

J Am Osteopath Assoc. 2015 Jul;115(7):452-8. doi: 10.7556/jaoa.2015.091.

PMID:
26111133
12.

Research in the osteopathic medical profession: roadmap to recovery-conundrums in osteopathic research require consensus and collaboration.

Walkowski SA, Eland DC, Hain S, Byron S.

J Am Osteopath Assoc. 2015 Feb;115(2):70-1. doi: 10.7556/jaoa.2015.016. No abstract available.

PMID:
25637612
13.
14.

Can upright myocardial perfusion imaging be used alone with a solid-state dedicated cardiac camera?

Hain SF, Van Gramberg D, Bomanji JB, Kayani I, Groves AM, Ben-Haim S.

Q J Nucl Med Mol Imaging. 2013 Dec;57(4):383-90. Epub 2013 Jun 11.

PMID:
23752688
15.

Dynamic contrast-enhanced MRI improves accuracy for detecting focal splenic involvement in children and adolescents with Hodgkin disease.

Punwani S, Cheung KK, Skipper N, Bell N, Bainbridge A, Taylor SA, Groves AM, Hain SF, Ben-Haim S, Shankar A, Daw S, Halligan S, Humphries PD.

Pediatr Radiol. 2013 Aug;43(8):941-9. doi: 10.1007/s00247-012-2616-7. Epub 2013 Feb 3.

PMID:
23377561
16.

Setup for single-particle orbit tracking: artifacts and corrections.

Ernst D, Hain S, Köhler J.

J Opt Soc Am A Opt Image Sci Vis. 2012 Jul 1;29(7):1277-87. doi: 10.1364/JOSAA.29.001277.

PMID:
22751393
17.

eHealth in Queensland: Progressing towards a Patient Centric, Networked Model of Care.

Shepherd T, Hain S.

Healthc Inform Res. 2011 Sep;17(3):190-5. doi: 10.4258/hir.2011.17.3.190. Epub 2011 Sep 30.

18.

18F-FDG PET to identify soft tissue disease in multiple myeloma.

Hain SF, Khan S, Stevenson W.

Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):553-4. doi: 10.1007/s00259-011-1957-z. Epub 2011 Oct 14. No abstract available.

PMID:
21997720
19.

Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study.

Geoerger B, Chisholm J, Le Deley MC, Gentet JC, Zwaan CM, Dias N, Jaspan T, Mc Hugh K, Couanet D, Hain S, Devos A, Riccardi R, Cesare C, Boos J, Frappaz D, Leblond P, Aerts I, Vassal G; European Consortium Innovative Therapies for Children with Cancer (ITCC).

Eur J Cancer. 2011 Jan;47(2):230-8. doi: 10.1016/j.ejca.2010.09.015. Epub 2010 Oct 11.

PMID:
20943374
20.

Simultaneous dual-radionuclide myocardial perfusion imaging with a solid-state dedicated cardiac camera.

Ben-Haim S, Kacperski K, Hain S, Van Gramberg D, Hutton BF, Erlandsson K, Sharir T, Roth N, Waddington WA, Berman DS, Ell PJ.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1710-21. doi: 10.1007/s00259-010-1441-1. Epub 2010 Apr 11.

21.

Pediatric and adolescent lymphoma: comparison of whole-body STIR half-Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging.

Punwani S, Taylor SA, Bainbridge A, Prakash V, Bandula S, De Vita E, Olsen OE, Hain SF, Stevens N, Daw S, Shankar A, Bomanji JB, Humphries PD.

Radiology. 2010 Apr;255(1):182-90. doi: 10.1148/radiol.09091105.

PMID:
20308456
22.

Quantitative diffusion weighted MRI: a functional biomarker of nodal disease in Hodgkin lymphoma?

Punwani S, Prakash V, Bainbridge A, Taylor SA, Bandula S, Olsen OE, Hain SF, Shankar A, Daw S, Humphries P.

Cancer Biomark. 2010;7(4):249-59. doi: 10.3233/CBM-2010-0197.

PMID:
21576817
23.

Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.

Geoerger B, Morland B, Ndiaye A, Doz F, Kalifa G, Geoffray A, Pichon F, Frappaz D, Chatelut E, Opolon P, Hain S, Boderet F, Bosq J, Emile JF, Le Deley MC, Capdeville R, Vassal G; Innovative Therapies for Children with Cancer European Consortium.

Eur J Cancer. 2009 Sep;45(13):2342-51. doi: 10.1016/j.ejca.2009.03.007. Epub 2009 Apr 9.

PMID:
19362466
24.

Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology.

Stauss J, Franzius C, Pfluger T, Juergens KU, Biassoni L, Begent J, Kluge R, Amthauer H, Voelker T, Højgaard L, Barrington S, Hain S, Lynch T, Hahn K; European Association of Nuclear Medicine.

Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1581-8. doi: 10.1007/s00259-008-0826-x. Erratum in: Eur J Nucl Med Mol Imaging. 2008 Nov;35(11):2140.

PMID:
18536914
25.

Guidelines for the use of PET-CT in children.

Barrington SF, Begent J, Lynch T, Schleyer P, Biassoni L, Ramsden W, Kane T, Stoneham S, Brooks M, Hain SF.

Nucl Med Commun. 2008 May;29(5):418-24. doi: 10.1097/MNM.0b013e3282f767b2. No abstract available.

PMID:
18391724
26.

18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group.

Huddart RA, O'Doherty MJ, Padhani A, Rustin GJ, Mead GM, Joffe JK, Vasey P, Harland SJ, Logue J, Daugaard G, Hain SF, Kirk SJ, MacKewn JE, Stenning SP; NCRI Testis Tumour Clinical Study Group.

J Clin Oncol. 2007 Jul 20;25(21):3090-5.

PMID:
17634488
27.

DXA scanning for osteoporosis.

Hain SF.

Clin Med (Lond). 2006 May-Jun;6(3):254-8. Review. No abstract available.

28.

Renal imaging.

Hain SF.

Clin Med (Lond). 2006 May-Jun;6(3):244-8. Review. No abstract available.

29.

Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer.

Sanghera B, Wong WL, Lodge MA, Hain S, Stott D, Lowe J, Lemon C, Goodchild K, Saunders M.

Nucl Med Commun. 2005 Oct;26(10):861-7.

PMID:
16160644
30.

Positron emission tomography in uro-oncology.

Hain SF.

Cancer Imaging. 2005 Jan 17;5:1-7.

31.

Oral contrast medium in PET/CT: should you or shouldn't you?

Groves AM, Kayani I, Dickson JC, Townsend C, Croasdale I, Syed R, Nagabushan N, Hain SF, Ell PJ, Bomanji JB.

Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1160-6. Epub 2005 Jun 4.

PMID:
15937685
32.

Positron emission tomography (PET) in the management of oro-pharyngeal cancer.

Jones J, Farag I, Hain SF, McGurk M.

Eur J Surg Oncol. 2005 Mar;31(2):170-6.

PMID:
15698734
33.

Localization of parathyroid adenomas using 11C-methionine positron emission tomography.

Beggs AD, Hain SF.

Nucl Med Commun. 2005 Feb;26(2):133-6.

PMID:
15657506
34.

Positron emission tomography in cancer of the head and neck.

Hain SF.

Br J Oral Maxillofac Surg. 2005 Feb;43(1):1-6.

PMID:
15620766
35.

C-11 methionine uptake in granulomatous disease.

Hain SF, Beggs AD.

Clin Nucl Med. 2004 Sep;29(9):585-6. No abstract available.

PMID:
15311134
36.
37.

Positron emission tomography with FDG to show thymic carcinoid.

Groves AM, Mohan HK, Wegner EA, Hain SF, Bingham JB, Clarke SE.

AJR Am J Roentgenol. 2004 Feb;182(2):511-3. No abstract available.

PMID:
14736691
38.

Use of co-registered 11C-methionine PET and computed tomography for the localisation of parathyroid adenomas.

Beggs AD, Hain SF.

Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1602. Epub 2003 Aug 23. No abstract available.

PMID:
14579103
39.

Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumours?

Hain SF, O'Doherty MJ, Bingham J, Chinyama C, Smith MA.

Nucl Med Commun. 2003 Nov;24(11):1139-43.

PMID:
14569167
40.

2-Fluorine-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography in the Pretreatment Staging of Hodgkin's Disease.

Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G.

Clin Positron Imaging. 1999 Nov;2(6):323. No abstract available.

PMID:
14516620
41.

Positron emission tomography for urological tumours.

Hain SF, Maisey MN.

BJU Int. 2003 Jul;92(2):159-64. Review.

42.

Validation of ultrafiltration as a method of measuring free 99mTc-MDP.

Moore AE, Hain SF, Blake GM, Fogelman I.

J Nucl Med. 2003 Jun;44(6):891-7.

43.

Nuclear medicine studies in metabolic bone disease.

Hain SF, Fogelman I.

Semin Musculoskelet Radiol. 2002 Dec;6(4):323-29. Review.

PMID:
12541189
44.

F-18 FDG-positron emission tomographic scanning and Wegener's granulomatosis.

Beggs AD, Hain SF.

Clin Nucl Med. 2002 Oct;27(10):705-6.

PMID:
12352111
45.

Bleomycin-induced alveolitis detected by FDG positron emission tomography.

Hain SF, Beggs AD.

Clin Nucl Med. 2002 Jul;27(7):522-3. No abstract available.

PMID:
12072783
46.

Functional imaging and the orthopaedic surgeon.

Hain SF, O'Doherty MJ, Smith MA.

J Bone Joint Surg Br. 2002 Apr;84(3):315-21. Review. No abstract available.

PMID:
12002485
47.

FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy.

Beggs AD, Hain SF, Curran KM, O'Doherty MJ.

Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):542-6. Epub 2002 Feb 27.

PMID:
11914894
48.

FDG-PET. A possible prognostic factor in head and neck cancer.

Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M.

Br J Cancer. 2002 Feb 12;86(4):512-6.

49.

The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders.

Rees JH, Hain SF, Johnson MR, Hughes RA, Costa DC, Ell PJ, Keir G, Rudge P.

Brain. 2001 Nov;124(Pt 11):2223-31.

PMID:
11673324
50.

FDG-PET as a "metabolic biopsy" tool in thoracic lesions with indeterminate biopsy.

Hain SF, Curran KM, Beggs AD, Fogelman I, O'Doherty MJ, Maisey MN.

Eur J Nucl Med. 2001 Sep;28(9):1336-40.

PMID:
11585292

Supplemental Content

Support Center